BUSINESS● LOWJul 27 · Jul 27, 2026, 11:49 AM
MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data
Seeking Alpha Tech
MapLight Therapeutics' stock price dropped significantly following the release of mixed phase 2 data for its schizophrenia treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS21m agoTrump says Pentagon will invest $1.5 billion into North Carolina chip productionThe HillBUSINESS29m agoEast West raises 2026 NII growth outlook to 9%-10% while cutting net charge-off guide to 15-20 bpsSeeking Alpha Tech